The Planning and Evaluation functions of the University of Colorado Cancer Center (UCCC) are conducted by groups of external and internal advisors who provide critical input and advice, both formal and informal, in the development of the programs and capabilities of the Cancer Center. The advice provided by these groups, along with the individual insight and information provided by UCCC leadership and other individuals and organizations, provides the substance from which the UCCC Strategic Plan is developed, implemented, evaluated, and revised. External advisory groups include the External Advisory Board (EAB), whose members include nationally recognized scientific experts in areas of cancer research of particular relevance to the research programs and shared resources of the UCCC as well as five Directors of NCI designated Cancer Centers. The Community Advisory Board (CAB) comprises business, community, and philanthropic leaders within the Denver region who are committed to the advancement of the center and play a major fundraising role. Other external advisory groups include specific EAB's for our Lung SPORE and developing large applications and individual consultants to provide advice and guidance on specific, strategic initiatives of the UCCC. Internal advisory groups engaged in planning and evaluation include the Internal Advisory Board (lAB), comprising both clinical and basic science department chairs or their representatives who meet quarterly with UCCC leadership. The Consortium Advisory Committee includes representatives from every UCCC consortium institution and assists in the development, implementation and evaluation of research initiatives of value to the UCCC consortium. Playing a principal role in internal planning and evaluation functions is the biweekly Executive Committee, consisting of the Director, Deputy Director, Senior Associate Director (AD) for Translational and Collaborative Research, and the AD's for Cancer Prevention and Control Clinical Services and Administration and Finance. Complementing the Executive Committee is the Governance Committee, convening monthly and comprising the Director, Deputy Director, all Associate Directors, Program Leaders and Shared Resource Directors. A number of Operational Committees provide input and evaluation to UCCC leadership on areas such as membership, protocol review and monitoring, clinical services, shared resource management, education, and seed grants. Other critical sources for planning and evaluation input are our center-wide and program retreats, seminar series, and symposia.

Public Health Relevance

NCl-designated Cancer Centers are the centerpiece of the national effort to reduce morbidity and mortality from cancer. As an NCl-designated Comprehensive Cancer Center, the University of Colorado Cancer Center (UCCC) is dedicated to the mission of developing more effective approaches to prevention, diagnosis, and therapy. Planning and Evaluation efforts of the UCCC provide the means through which strategic decision-making and subsequent implementation are conducted to accomplish the UCCC mission.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046934-24
Application #
8465397
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-06
Project End
2017-01-31
Budget Start
2012-08-06
Budget End
2013-01-31
Support Year
24
Fiscal Year
2012
Total Cost
$15,955
Indirect Cost
$5,415
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Tuttle, Kathryn D; Krovi, S Harsha; Zhang, Jingjing et al. (2018) TCR signal strength controls thymic differentiation of iNKT cell subsets. Nat Commun 9:2650
Keysar, Stephen B; Eagles, Justin R; Miller, Bettina et al. (2018) Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. Clin Cancer Res 24:2935-2943
Salmon, Loïc; Stull, Frederick; Sayle, Sabrina et al. (2018) The Mechanism of HdeA Unfolding and Chaperone Activation. J Mol Biol 430:33-40
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
Steckelberg, Anna-Lena; Akiyama, Benjamin M; Costantino, David A et al. (2018) A folded viral noncoding RNA blocks host cell exoribonucleases through a conformationally dynamic RNA structure. Proc Natl Acad Sci U S A 115:6404-6409
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Antonioli, Alexandra H; White, Janice; Crawford, Frances et al. (2018) Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins. J Immunol 200:316-326
Boswell, Zachary K; Rahman, Samiur; Canny, Marella D et al. (2018) A dynamic allosteric pathway underlies Rad50 ABC ATPase function in DNA repair. Sci Rep 8:1639
Fitzwalter, Brent E; Towers, Christina G; Sullivan, Kelly D et al. (2018) Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a Turnover. Dev Cell 44:555-565.e3
Duex, Jason E; Swain, Kalin E; Dancik, Garrett M et al. (2018) Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer. Mol Cancer Res 16:69-77

Showing the most recent 10 out of 1634 publications